A BILL to direct the Department of Medical Assistance Services to determine the feasibility of participating in an optional Medicaid benefit for sickle cell disease and establishing Medicaid Health Homes to coordinate care and provide treatment for individuals with sickle cell disease; report.
HB136 directs the Virginia Department of Medical Assistance Services (DMAS) to study whether the Commonwealth should participate in an optional Medicaid benefit for sickle cell disease and whether it should establish Medicaid Health Homes for people with sickle cell disease. The bill does not itself create the benefit or the health homes; instead, it requires DMAS to evaluate feasibility and include its findings in an annual review of medications, treatments, and covered services for Medicaid enrollees diagnosed with sickle cell disease.
The required report must be submitted by November 15, 2026, to the chairs of the House Committee on Health and Human Services, the Senate Committee on Education and Health, and the Joint Commission on Health Care. In practical terms, the bill is a policy study and reporting measure focused on improving care coordination and treatment access for Medicaid members with sickle cell disease, rather than an immediate coverage mandate.
HB136 would affect the Department of Medical Assistance Services by adding a new evaluation and reporting duty related to sickle cell disease coverage and care coordination under Medicaid. It would not directly amend eligibility rules or require immediate service expansion, but it could lay the groundwork for future Medicaid policy changes, including optional federal benefit participation and the creation of Medicaid Health Homes for this population. The bill’s impact is therefore procedural and preparatory, with potential downstream effects on covered services, provider coordination, and state Medicaid administration.
The available record suggests generally favorable or at least noncontroversial treatment of the bill, but there is limited evidence of debate because no committee transcript or vote history is provided. Its focus on studying improved care for individuals with sickle cell disease and on Medicaid coordination suggests a policy goal likely to attract support from health advocates and affected families. However, the bill was left in the Committee on Appropriations, indicating that fiscal considerations or competing budget priorities may have limited its advancement.
The main point of potential contention is cost and administrative feasibility. Because the bill asks DMAS to determine whether Virginia should participate in an optional Medicaid benefit and establish Medicaid Health Homes, lawmakers may have concerns about implementation expenses, staffing, and the broader fiscal impact on the Medicaid program. Another possible issue is whether the state should move from study to action without clearer estimates of enrollment, provider capacity, and expected health outcomes. No specific opposing arguments are documented in the provided materials.